News Article

Swiss-listed HBM Healthcare Investments has agreed to sell a majority stake in Swixx Biopharma, a specialised distributor of rare diseases, prescription and over the counter medicinal products to US-based SK Capital Partners.

This marks a strategic milestone for both parties as the pharma commercialisation platform accelerates global expansion.

The transaction, valued at over €1.5bn, will see HBM, Swixx’s founders, and co-investors like Mérieux Equity Partners retain significant minority ownership while SK Capital assumes majority control.

HBM’s investment has generated CHF 300m (€322m) in added value – over ten times the original outlay – amid Swixx’s impressive revenue growth from EUR 40 million (2017) to an expected EUR 1.3 billion (2026). The platform, operating in 45 countries across Central/Eastern Europe, Eurasia, the Middle East, and Latin America, has become a leader in commercialising rare disease, oncology-haematology, and specialty therapies for global biopharma clients.

Notably, HBM will retain its 25.1% stake in Swixx Healthcare , a spin-off entity focused on complementary services, while Swixx’s co-founders and executive team – including CEO Jean-Michel Lespinasse – will maintain leadership roles and equity stakes.

Dr. Andreas Wicki, HBM CEO, emphasized confidence in Swixx’s trajectory: “We are excited to build on the strong momentum as we pursue the next phase of accelerated growth and long-term value creation for the innovation-based pharma industry.”

SK Capital’s Aaron Davenport highlighted synergies: “Our investment underscores confidence in Swixx’s leadership and its ability to deliver sustainable business growth across diverse markets.”

The partnership aims to expand Swixx’s footprint in underserved regions while preserving its core strategy of serving as a “trusted multi-regional commercialisation partner” for biotech innovators.